...
首页> 外文期刊>Nutrition & Diabetes >Treatment with FGFR2-IIIc monoclonal antibody suppresses weight gain and adiposity in KKAy miceOpen
【24h】

Treatment with FGFR2-IIIc monoclonal antibody suppresses weight gain and adiposity in KKAy miceOpen

机译:用FGFR2-IIIc单克隆抗体治疗可抑制KKAy小鼠的体重增加和肥胖

获取原文

摘要

Expression of β-Kotho, fibroblast growth factor receptor (FGFR)-1c and 2c, which bind FGF21, is decreased in the white adipose tissue of obese mice. The aim of the present study was to determine the role of FGFR2c in the development of obesity and diabetes in KKAy mice. Treatment with mouse monoclonal FGFR2-IIIc antibody (0.5?mg?kg?1) significantly suppressed body weight gain and epididymal white adipose tissue weight in individually housed KKAy mice while having no effect on daily food intake. In addition, treatment with FGFR2-IIIc antibody significantly increased plasma-free fatty acid levels while having no effect on blood glucose or plasma FGF21 levels. Moreover, treatment with FGFR2-IIIc antibody had no significant effect on the expression of uncoupling protein-1, uncoupling protein-2 or peroxisome proliferator-activated receptor-γ coactivator 1α in the epididymal white adipose tissue. The treatment with FGFR2-IIIc antibody had no significant effects on daily food intake and body weight gain in individually housed KK mice. These findings suggest that FGFR2-IIIc upregulates the adiposity induced by social isolation in KKAy mice, and that decreased expression and/or function of FGFR2c might be a compensatory response to enhanced adiposity. Inhibition of FGFR2-IIIc function might be a novel therapeutic approach for obesity.
机译:在肥胖小鼠的白色脂肪组织中,与FGF21结合的β-Kotho,成纤维细胞生长因子受体(FGFR)-1c和2c的表达降低。本研究的目的是确定FGFR2c在KKAy小鼠肥胖和糖尿病发展中的作用。用小鼠单克隆FGFR2-IIIc抗体(0.5?mg?kg?1)处理可显着抑制单独饲养的KKAy小鼠的体重增加和附睾白色脂肪组织重量,而对每日食物摄入量没有影响。另外,用FGFR2-IIIc抗体治疗显着增加了血浆中游离脂肪酸的水平,而对血糖或血浆FGF21水平没有影响。此外,用FGFR2-IIIc抗体处理对附睾白色脂肪组织中解偶联蛋白-1,解偶联蛋白-2或过氧化物酶体增殖物激活的受体-γ共激活因子1α的表达没有显着影响。用FGFR2-IIIc抗体进行的处理对单独饲养的KK小鼠的日常食物摄入和体重增加没有明显影响。这些发现表明,FGFR2-IIIc上调了KKAy小鼠的社交隔离诱导的肥胖,而FGFR2c的表达和/或功能下降可能是对肥胖增加的补偿性反应。 FGFR2-IIIc功能的抑制可能是肥胖的一种新型治疗方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号